Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Liraglutide vs Survodutide: Liraglutide has the stronger overall evidence (7.5 vs 5.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Liraglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Liraglutide and Survodutide have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.
any
Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)
Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
Weeks to months
Months (titrated over weeks)
Months to years
Especially during dose escalation
Progressive over 24-46 weeks
By 48 weeks
By 16-46 weeks
Especially during dose escalation
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).
N Engl J Med (2016) · Rct · n=9340
Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide (up to 1.8 mg/day) vs placebo, median follow-up 3.8 years
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).
N Engl J Med (2015) · Rct · n=3731
56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
JAMA (2015) · Rct · n=846
56-week double-blind RCT in 846 adults with overweight/obesity AND type 2 diabetes, liraglutide 3.0 mg vs 1.8 mg vs placebo (2:1:1)
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
N Engl J Med (2024) · Rct · n=293
48-week phase-2, double-blind, randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3, once-weekly subcutaneous survodutide 2.4/4.8/6.0 mg vs placebo with a 24-week rapid-escalation then 24-week maintenance design
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Lancet Diabetes Endocrinol (2024) · Rct · n=387
Phase-2, double-blind, randomized, placebo-controlled dose-finding trial in 387 adults with obesity (BMI ≥27) across 43 centres in 12 countries, once-weekly subcutaneous survodutide 0.6-4.8 mg vs placebo for 46 weeks
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia (2024) · Rct · n=413
Phase-2, multicentre, double-blind, randomized, placebo-controlled dose-response trial in 413 adults with type 2 diabetes, once-weekly subcutaneous survodutide across six dose groups vs placebo, with an open-label semaglutide reference arm
Liraglutide has a higher evidence score (7.5/10 vs 5.5/10) and wins in 2 of 3 categories.
For manage blood sugar, Liraglutide has a higher relevance score (80 vs 48).
No known interactions between Liraglutide and Survodutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.